Icon

XERMELO (nda208794)- (EQ 250MG BASE)

TELOTRISTAT ETIPRATE TERSERA
EQ 250MG BASE
No No
2031-Feb-28 2022-Feb-28
2024-Feb-28 None
None No
Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
0 0 0
Total Other Developers None
Drugs with Suitability No
EQ 250MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.